All In Biotech

Drug Trial Radar · NCT06551181

A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older

A Phase 3, Randomized, Controlled, Partially Blind, Immuno-bridging Study to Evaluate Immunogenicity, Reactogenicity, Safety and the Occurrence of RSV Associated Respiratory Tract Illness After Administration of a Single Dose of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Older

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,620 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,620

Actual

Start

Aug 5, 2024

Primary completion

Apr 24, 2025

Study completion Sep 15, 2025

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Aug 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the current study is to evaluate the immune response of the RSVPreF3 OA investigational vaccine in older adults (OA) at least (\>=) 60 years of age (YOA) in China compared to OA in the same age range to be enrolled from overseas countries that participated in the RSV OA=ADJ-006 (NCT04886596) study, since the vaccine efficacy against lower respiratory tract disease (LRTD) has been demonstrated following a single dose of the RSVPreF3 OA investigational vaccine in the global efficacy study RSV OA=ADJ-006. In addition, the safety (in all participants) , reactogenicity and occurrence of RSV-associated acute respiratory illness (ARI) (in study participants in China only) after administration of the vaccine are also assessed in the current study. No ARI surveillance will be conducted for the overseas participants.

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

  • RSVPreF3 OA investigational vaccineBiological

    One dose of the RSVPreF3 OA investigational vaccine is administered intramuscularly at Day 1.

  • Placebo (Saline solution)Drug

    One dose of placebo is administered intramuscularly at Day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RSV-A Neutralizing Titers Expressed as Adjusted Geometric Mean Titers (GMTs) at 1 Month Post RSVPreF3 OA VaccinationTime frame: At Day 31
  2. Percentage of Participants With Seroresponse for RSV-A Neutralizing Titers at 1 Month Post RSVPreF3 OA VaccinationTime frame: At Day 31 compared to baseline (Day 1)
  3. RSV-B Neutralizing Titers Expressed as Adjusted GMTs at 1 Month Post RSVPreF3 OA VaccinationTime frame: At Day 31
  4. Percentage of Participants With Seroresponse for RSV-B Neutralizing Titers at 1 Month Post RSVPreF3 OA VaccinationTime frame: At Day 31 compared to baseline (Day 1)

Locations

40 sites in 7 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Shanghai, China

  • GSK Investigational Site

    Shanghai, China

  • GSK Investigational Site

    Shanghai, China

  • GSK Investigational Site

    Shanghai, China

  • GSK Investigational Site

    Shanghai, Putuo, China

  • GSK Investigational Site

    Shanghai, Putuo, China

  • GSK Investigational Site

    Shanghai, Shanghai Municipality, China

  • GSK Investigational Site

    Espoo, Finland

  • GSK Investigational Site

    Helsinki, Finland

  • GSK Investigational Site

    Kokkola, Finland

  • GSK Investigational Site

    Oulu, Finland

  • GSK Investigational Site

    Seinäjoki, Finland

  • GSK Investigational Site

    Tampere, Finland

  • GSK Investigational Site

    Turku, Finland

  • GSK Investigational Site

    Tokyo, Japan

  • GSK Investigational Site

    Elblag, Poland

  • GSK Investigational Site

    Katowice, Poland

  • GSK Investigational Site

    Katowice, Poland

  • GSK Investigational Site

    Krakow, Poland

  • GSK Investigational Site

    Lodz, Poland

  • GSK Investigational Site

    Lublin, Poland

  • GSK Investigational Site

    Sochaczew, Poland

  • GSK Investigational Site

    Warsaw, Poland

  • GSK Investigational Site

    Wroclaw, Poland

  • GSK Investigational Site

    Guri-si, South Korea

  • GSK Investigational Site

    Incheon, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Ávila, Spain

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Burgos, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Salamanca, Spain

  • GSK Investigational Site

    Valladolid, Spain

  • GSK Investigational Site

    Belfast, United Kingdom

  • GSK Investigational Site

    Blackpool, United Kingdom

  • GSK Investigational Site

    Bristol, United Kingdom

  • GSK Investigational Site

    Cambridgeshire, United Kingdom

  • GSK Investigational Site

    Hounslow, United Kingdom

  • GSK Investigational Site

    Witney, United Kingdom

  • GSK Investigational Site

    Witney, Oxfordshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.